New Orleans, LA, USA—May 21, 2019—ISPOR, the professional
society for health economics and outcomes research (HEOR), examined how
real-world evidence can be improved with patient-provided information this
afternoon at its ISPOR 2019 annual conference with
the session [W13], “Leveraging Patient-Provided Information to Improve
Real-World Evidence: Getting to Good Practices on How.”
Despite agreement that
patient experiences should inform real-world study designs, best practices are
lacking on exactly how patient-provided information (PPI) translates into
improved real-world evidence (RWE) studies. Discussion leaders for the session
included:
- Cristina Masseria, MSc PhD; Pfizer; New York, NY, USA
- Elisabeth Oehrlein, PhD, MS; National Health Council; Washington, DC, USA
- Chris L. Pashos, PhD; AbbVie US LLC; North Chicago, IL, USA
- Richard J. Willke, PhD; ISPOR; Lawrenceville, NJ, USA
ISPOR partnered with the
International Society for Pharmacoepidemiology (ISPE) to form a Joint Special
Task Force on Real-World Evidence in Healthcare Decision Making. ISPOR and ISPE
held a Summit in October 2017 on this issue and the Special Task Force produced
and published 2 papers and an editorial in this area.
As part of their
objective to improve the rigor of RWE, the Joint ISPOR-ISPE Special Task Force
recommended that stakeholder engagement be included for good procedural
practices when designing, conducting, and disseminating RWE. Good practices
exist on how to collect patient input, but do not exist on translating the
input into specific study-design and/or methods considerations. To accomplish
patient centricity in RWE, an urgent need exists to explore how to best
translate PPI into specific study considerations.
Dr Willke reviewed the intent
of the ISPOR/ISPE Special Task Force’s recommendations for researchers and
perspectives on moving the field forward. Dr Oehrlein provided an overview of
the topic with a case study on incorporating atrial fibrillation patient
experiences into an RWE study design. Drs Masseria and Pashos built on their experiences to offer suggestions
for incorporating PPI into RWE study designs using different types of datasets
for different markets. The discussion leaders then facilitated a group
discussion based on specific examples of how RWE study designs can benefit from
patient-provided input. Dr Willke stated, “Employing patient insights into the
disease and treatment situation is invaluable for designing a meaningful,
impactful real-world study.”
ISPOR is recognized
globally as the leading professional society for health economics and outcomes
research and its role in improving healthcare decisions. ISPOR 2019 is the
leading global HEOR conference and draws nearly 4000 healthcare thought leaders
and stakeholders, including researchers and academicians, assessors and
regulators, payers and policy makers, the life sciences industry, healthcare
providers, and patient engagement organizations.
Additional information on the conference can be found at:
Conference Information | Program | Registration | Short Course Program | Sponsors | Exhibitors | Press
###
ABOUT
ISPOR
ISPOR, the professional society for health economics
and outcomes research (HEOR), is an international, multistakeholder, nonprofit
dedicated to advancing HEOR excellence to improve decision making for health
globally. The Society is the leading source for scientific conferences,
peer-reviewed and MEDLINE®-indexed publications, good practices guidance,
education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg